February 2023
« Back to 2023
–
Friday, February 24, 2023
Matthew Herder and colleagues critically analyze the basis upon which Health Canada approved OxyContin.
–
Friday, February 24, 2023
In this posted letter, Matthew Herder explains his reasons for resigning from the Patented Prices Review Board on Mon. 20 Feb 2023.
–
Friday, February 24, 2023
Matthew Herder and colleagues critically review the regulatory history of buprenorphine formulations in Canada.
–
Thursday, February 23, 2023
Matthew Herder and colleagues publish on the topic of fair pricing and Canada's orphan drug policy.